Medical cannabis linked to improved pain, mood and sleep in 24-week Canadian study
Feb 27th 2026
An observational Canadian study of 139 authorized medical cannabis patients found sustained reductions in pain, anxiety and depression and improved sleep and quality of life over 24 weeks, with few reported adverse events.
- Study tracked 139 patients authorized for medical cannabis with assessments at baseline, 6, 12 and 24 weeks.
- Patients showed sustained improvements in pain, pain-related disability, anxiety, depression, sleep duration and overall quality of life.
- Benefits were maintained through week 24 according to the study authors.
- Few significant adverse events were reported during the 24-week follow-up.
- The study is observational and lacks a randomized control group, which limits causal conclusions.
- A separate meta-analysis of 64 studies also found that most patients report sustained quality of life improvements with medical cannabis.